Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G D Novack

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Current Opinion in Ophthalmology|November 3, 1997
Ocular toxicologyG D Novack
American Journal of Ophthalmology|July 31, 1998
Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug AdministrationG D Novack
Journal of Glaucoma|April 27, 2000
Financing new drug development in ophthalmologyG D Novack
JAMA|April 3, 1996
Excessive beta-blockade with timolol eye dropsG D Novack
Survey of Ophthalmology|March 1, 1987
Ophthalmic beta-blockers since timololG D Novack
Clinical Pharmacology and Therapeutics|February 20, 2009
Ophthalmic drug delivery: development and regulatory considerationsG D Novack
Clinical Pharmacology and Therapeutics|April 1, 1993
Industrial publication of controlled clinical trial dataG D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 8, 1998
Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administrationJ Howes, G D Novack
Journal of Glaucoma|December 12, 2001
Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilizationG D Novack, R Evans
American Journal of Ophthalmology|September 15, 1987
Aqueous humor, cerebrospinal fluid, and atriopeptinG D Novack, I H Leopold
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Current Opinion in Ophthalmology|November 3, 1997
Ocular toxicologyG D Novack
American Journal of Ophthalmology|July 31, 1998
Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug AdministrationG D Novack
Journal of Glaucoma|April 27, 2000
Financing new drug development in ophthalmologyG D Novack
JAMA|April 3, 1996
Excessive beta-blockade with timolol eye dropsG D Novack
Survey of Ophthalmology|March 1, 1987
Ophthalmic beta-blockers since timololG D Novack
Clinical Pharmacology and Therapeutics|February 20, 2009
Ophthalmic drug delivery: development and regulatory considerationsG D Novack
Clinical Pharmacology and Therapeutics|April 1, 1993
Industrial publication of controlled clinical trial dataG D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 8, 1998
Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administrationJ Howes, G D Novack
Journal of Glaucoma|December 12, 2001
Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilizationG D Novack, R Evans
American Journal of Ophthalmology|September 15, 1987
Aqueous humor, cerebrospinal fluid, and atriopeptinG D Novack, I H Leopold
Pageof 8